Investor Relations News
2026
- Jun 18, 2026 Notice Regarding Application for Marketing Authorization Holder License for Regenerative Medical Products
- Jun 11, 2026 Notice Regarding Finalization of the FY2025 Grant Amount for AMED Public Offering Project "Development of Infrastructure Technology for the Industrialization of Regenerative Medicine and Gene Therapy"
- May 27, 2026 Notice Regarding the Execution of an Equity Program Agreement, the Filing of Shelf Registration Statements, and the Issuance of New Shares and Stock Acquisition Rights through Third-Party Allotment
- May 22, 2026 Notice Concerning Grant Awarded to Consolidated Subsidiary (REPROCELL USA Inc.)
- Apr 02, 2026 Notice Regarding Selection for AMED Public Offering Project: "Development of Infrastructure Technology for the Industrialization of Regenerative Medicine and Gene Therapy"
- Mar 23, 2026 Notice Regarding the Commencement of Manufacturing and Sales of Neoantigen-Derived Peptides
- Mar 11, 2026 Notice Regarding Commencement of U.S. Phase II Clinical Trial for Stemchymal® Stem Cell Drug by Investee (Steminent Biotherapeutics Inc.) and Progress of Global Expansion
- Mar 02, 2026 Notice Concerning the Launch of GMP Master Cell Bank (MCB) Manufacturing Services for Clinical iPSCs
- Feb 12, 2026 Notice Regarding Revision of Financial Forecasts
- Feb 12, 2026 Consolidated Financial Results for the Nine Months Ended December 31, 2025 (Under Japanese GAAP)
- Jan 27, 2026 Notice Regarding the Launch of "Middle Conditioning Program," a New Service Under the Healthcare Brand "WELLMILL"
- Jan 27, 2026 Notice Regarding the Launch of "StemEdit," a Clinical-Grade Gene Editing Service
- Jan 26, 2026 Notice Regarding the Launch of "Genetic Age Measurement Kit," a New Service to Scientifically Visualize Biological Age